Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Quote. Delayed Nasdaq - 10/15 04:00:00 pm
98.96 USD   +1.24%
10/11EXACT SCIENCES : Hosts Maydm Interns
PU
10/08EXACT SCIENCES : schedules third quarter 2021 earnings call
PR
10/07ONCOCYTE : Names Gisela Paulsen as Operations Chief
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
93.45(c) 96.24(c) 97.34(c) 97.75(c) 98.96(c) Last
721 944 1 322 802 990 279 1 096 291 1 026 444 Volume
-0.26% +2.99% +1.14% +0.42% +1.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 732 M - -
Net income 2021 -493 M - -
Net Debt 2021 1 374 M - -
P/E ratio 2021 -33,2x
Yield 2021 -
Sales 2022 2 091 M - -
Net income 2022 -488 M - -
Net Debt 2022 1 558 M - -
P/E ratio 2022 -36,0x
Yield 2022 -
Capitalization 17 016 M 17 016 M -
EV / Sales 2021 10,6x
EV / Sales 2022 8,88x
Nbr of Employees 4 900
Free-Float 99,2%
More Financials
Company
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to... 
More about the company
Ratings of Exact Sciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXACT SCIENCES CORPORATION
10/11EXACT SCIENCES : Hosts Maydm Interns
PU
10/08EXACT SCIENCES : schedules third quarter 2021 earnings call
PR
10/07ONCOCYTE : Names Gisela Paulsen as Operations Chief
MT
10/05INSIDER SELL : Exact Sciences
MT
09/15EXACT SCIENCES : Hires Sales Employees From Pfizer for Cologuard Promotion; Shares Up
MT
09/15Exact Sciences in Talks With Pfizer Amid Cologuard Sales-Force Changes
DJ
09/14Exact Sciences Corporation and National Surgical Adjuvant Breast and Bowel Project Anno..
CI
09/02EXACT SCIENCES : to Present New Oncotype DX Genomic Prostate Score« Test Data and Exhibit ..
PU
09/01EXACT SCIENCES : to participate in September investor conferences
PR
08/30RENALYTIX : Appoints Daniel J. Levangie to its Board of Directors
AQ
08/16EXACT SCIENCES' : Cancer Test Related to Chemo Therapy Recommendations Gets Regulatory App..
MT
08/16EXACT SCIENCES : receives regulatory approval for the Oncotype DX Breast Recurrence Score«..
PR
08/16Exact Sciences Receives Regulatory Approval for the Oncotype DX Breast Recurrence Score..
CI
08/13EXACT SCIENCES : Says Study Shows Its Liver Liquid Biopsy Test Delivers 82% Early-Stage Se..
MT
08/13Exact Sciences Corp. Announces the Performance of its OncoguardÖ Liver Liquid Biopsy Te..
CI
More news
News in other languages on EXACT SCIENCES CORPORATION
10/05VENTE D'INITIÉS : Exact Sciences
09/15Exact Sciences embauche des employés des ventes de Pfizer pour la promotion de Cologuar..
08/09EN DIRECTO DESDE LOS MERCADOS : Sika, ByteDance, Renault, Logitech, PostNL, Aramco, Philip..
08/09MADRID STOCK EXCHANGE : Resultados casi perfectos
08/09STOCK MARKET PARIS : Des résultats presque parfaits
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 98,96 $
Average target price 142,35 $
Spread / Average Target 43,8%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors